BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 26403791)

  • 1. Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.
    Huang Y; Wu Z; Zhou B
    Cell Mol Life Sci; 2016 Jan; 73(1):1-21. PubMed ID: 26403791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
    Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
    Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
    Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
    Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Tau Proteoforms in Health and Disease.
    Waheed Z; Choudhary J; Jatala FH; Fatimah ; Noor A; Zerr I; Zafar S
    Mol Neurobiol; 2023 Sep; 60(9):5155-5166. PubMed ID: 37266762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sources of extracellular tau and its signaling.
    Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
    J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.
    Reilly P; Winston CN; Baron KR; Trejo M; Rockenstein EM; Akers JC; Kfoury N; Diamond M; Masliah E; Rissman RA; Yuan SH
    Neurobiol Dis; 2017 Oct; 106():222-234. PubMed ID: 28610892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are tangles as toxic as they look?
    Spires-Jones TL; Kopeikina KJ; Koffie RM; de Calignon A; Hyman BT
    J Mol Neurosci; 2011 Nov; 45(3):438-44. PubMed ID: 21638071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau-based treatment strategies in neurodegenerative diseases.
    Schneider A; Mandelkow E
    Neurotherapeutics; 2008 Jul; 5(3):443-57. PubMed ID: 18625456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau as a therapeutic target for Alzheimer's disease.
    Boutajangout A; Sigurdsson EM; Krishnamurthy PK
    Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
    Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
    Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies.
    de Silva R; Lashley T; Gibb G; Hanger D; Hope A; Reid A; Bandopadhyay R; Utton M; Strand C; Jowett T; Khan N; Anderton B; Wood N; Holton J; Revesz T; Lees A
    Neuropathol Appl Neurobiol; 2003 Jun; 29(3):288-302. PubMed ID: 12787326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.